The US Food and Drug Administration (FDA) has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children. RPDs are designed to encourage the development of new drugs with high unmet medical needs, including rare diseases in children. The […]
Menu ≡ ╳ 
